for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CEL-SCI Corporation

CVM.A

Latest Trade

21.51USD

Change

0.10(+0.47%)

Volume

65,218

Today's Range

20.92

 - 

21.85

52 Week Range

10.78

 - 

40.91

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
21.41
Open
21.00
Volume
65,218
3M AVG Volume
20.70
Today's High
21.85
Today's Low
20.92
52 Week High
40.91
52 Week Low
10.78
Shares Out (MIL)
42.53
Market Cap (MIL)
910.55
Forward P/E
-33.45
Dividend (Yield %)
--

Next Event

Q3 2021 CEL-SCI Corp Earnings Release

Latest Developments

More

CEL-SCI Announces Bought Deal Offering

CEL-SCI Reports Q2 Loss Per Share Of $0.28

CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CEL-SCI Corporation

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Industry

Biotechnology & Drugs

Contact Info

8229 Boone Blvd Ste 802

VIENNA, VA

22182-2634

United States

+1.703.5069460

http://www.cel-sci.com/

Executive Leadership

Geert R. Kersten

Chief Executive Officer, Treasurer, Director

Patricia B. Prichep

Senior Vice President - Operations, Corporate Secretary

John Cipriano

Senior Vice President - Regulatory Affairs

Daniel H. Zimmerman

Senior Vice President - Research, Cellular Immunology

Eyal Talor

Chief Scientific Officer

Key Stats

Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.870

2019

-0.710

2021(E)

1.050
Price To Earnings (TTM)
--
Price To Sales (TTM)
4,057.16
Price To Book (MRQ)
29.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
41.10
LT Debt To Equity (MRQ)
41.10
Return on Investment (TTM)
-94.81
Return on Equity (TTM)
-82.44

Latest News

Latest News

BRIEF-CEL-SCI Corporation Receives $10 Million Through Warrant Exercises

* CEL-SCI CORPORATION RECEIVES $10 MILLION THROUGH WARRANT EXERCISES Source text for Eikon: Further company coverage:

BRIEF-Cel-Sci Corp Reports Q2 Loss Per Share Of $0.25

* CEL-SCI CORPORATION REPORTS SECOND QUARTER FISCAL 2020 FINANCIAL RESULTS

BRIEF-Cel-Sci’S Pivotal Phase 3 Study Has Reached The Required Number Of Events To Evaluate Data

* CEL-SCI’S PIVOTAL PHASE 3 STUDY HAS REACHED THE REQUIRED NUMBER OF EVENTS TO EVALUATE DATA FOR MULTIKINE IN TREATMENT OF HEAD AND NECK CANCER Source text for Eikon: Further company coverage:

BRIEF-Cel-Sci Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

* CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

BRIEF-Cel-Sci Corp Says Annual Stockholders Meeting Will Still Be Held On April 17, 2020 At 1030 A.M. ET, But In A Hybrid Meeting Format

* CEL-SCI CORP - ANNUAL STOCKHOLDERS MEETING WILL STILL BE HELD ON APRIL 17, 2020 AT 10:30 A.M. ET, BUT IN A HYBRID MEETING FORMAT Source text for Eikon: Further company coverage:

BRIEF-Cel-Sci Corp Offering 630,500 Shares Of Common Stock

* CEL-SCI CORP - OFFERING 630,500 SHARES OF COMMON STOCK FOR PRICE EQUAL TO $12.22 PER SHARE Further company coverage:

BRIEF-Cel-Sci Corp Files Preliminary Prospectus Supplement Related To Common Stock Offering Size Undisclosed - SEC Filing

* CEL-SCI CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO COMMON STOCK OFFERING; SIZE UNDISCLOSED - SEC FILING Source text: (https://bit.ly/2UiuKQl) Further company coverage:

BRIEF-Cel-Sci Announces Bought Deal Offering

* CEL-SCI - UNDERWRITING AGREEMENT WITH AEGIS CAPITAL; UNDERWRITER AGREED TO PURCHASE MINIMUM OF 500,000 SHARES OF CO'S COMMON STOCK AT $12.22/ SHARE Source text for Eikon: Further company coverage:

BRIEF-Cel-Sci To Develop Leaps COVID-19 Immunotherapy In Collaboration With University Of Georgia Center For Vaccines And Immunology

* CEL-SCI TO DEVELOP LEAPS COVID-19 IMMUNOTHERAPY IN COLLABORATION WITH UNIVERSITY OF GEORGIA CENTER FOR VACCINES AND IMMUNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Cel-Sci Corporation Issues Letter To Shareholders

* CEL-SCI - TO HELP EVALUATE FACTORS CONTRIBUTING TO BETTER THAN EXPECTED SURVIVAL IN PHASE 3 STUDY, CO ENGAGED AN INDEPENDENT STATISTICAL GROUP

BRIEF-CEL-SCI Corp Reports Q1 Loss Per Share Of $0.16

* CEL-SCI CORPORATION REPORTS FIRST QUARTER FISCAL 2020 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up